GSTM1 and anemia: A significant increase in plasma 25OHD (40.1 ± 17.8, <i>p</i> < 0.001) and in Hb (12.4 ± 2.0, <i>p</i> = 0.01) was observed at 3 months with a decrease in the prevalence of anemia (n = 17, <i>p</i> = 0.015) and of Interleukin 6 in plasma levels [IL-6, 10.7 (5.8-23.3) vs. 6.5 (4.1-11.8), <i>p</i> = 0.016].